DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
LOS ANGELES, April 06, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Kitov Pharmaceuticals Holdings LTD (“Kitov” or the “Company”) (Nasdaq:KTOV) concerning possible violations of federal securities laws. Investors who purchased Kitov American Depositary Receipts (“ADRs”) pursuant to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), should contact the firm prior to the April 10, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that during the Class Period, Kitov made false and/or misleading statements and/or failed to disclose that the Company and its CEO Isaac Israel, published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate, KIT-302, and consequently, Kitov’s public statements were materially false and misleading at all relevant times.
On February 6, 2017, Calcalist, an Israeli publication, reported that Isaac Israel had been detained and questioned by the Israeli Securities Authority for allegedly publishing misleading information about the Company’s recent clinical trial. When this news information reached the investing public, Kitov’s stock price declined.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
